12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

More documents

Recommendations

Info

Resultaterne fra de foreliggende studier er således modstridende, hvorfor denne behandlingsmodalitet forsat må betragtes som eksperimentel og så vidt muligt bør foregå protokolleret. Udenfor protokol kan mini-KMT dog overvejes hos meget unge patienter med kemoterapifølsom sygdom. Transplantationen bør gennemføres tidligt i forløbet og sekventielt efter en autolog transplantation med en HLA-identisk søskende donor eller alternativt med en ubeslægtet donor (MUD) med HLA-A, -B, -C, -DRB1 og DQB1 0-1 locus allelforligelighed. Referencer Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB, Omri HEO, Elloumi M, Belaaj H, Jeddi R, Aissaoui L, Ksouri H, Hassen AB, Msadek F, Saad A, Hsairi M, Boukef K, Amouri A, Louzir H, Dellagi K, Abdeladhim AB on behalf of the Tunisian Myeloma Study Group. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008; 111: 1805-10. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-502. Attal M, Harousseau JL, Levyraz S, Doyen C, Hulin C, Benboubker L, Agha IY, Bourhis JH, Garderet L, Pegourie B, DumontetC, Renaud M, Voillat L, Berthou C, Marit G, Monconduit M, Caillot D, Grobois B, Avet- Loiseau H, Moreau P, Facon T for the Inter-Groupe Francophone du Myélome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. 2006 Blood; 108: 3289-94. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822-9. Badros A, Barlogie B, Siegel E et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-303. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue in multiple myeloma. N Engl J Med 2003; 348; 1875-83. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Ormedè P, Baldi I, Bringhen S, Massaia M, Aglietta M, Levis A, Gallamini A, Famin R, Palumbo A, Storb R, Ciccone G, Boccadoro M. A comparison of allografting with autograftin for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110-20. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A, Casini M, parma M, bavaro P, Onida F, Busca F, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo A, Corradini P, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of te Gruppo Italiano Trapianti di Midollo. Blood 2009; 113: 3375- 82. 102
Cavo M, Tosi P, Zagmani E, Cellini C, Tacchette P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S, Cangini D, Narni F, Carubelli A, Masini L, Catalano L, Fiacchini M, de Vivo A, Gozzetti A, Lazzaro A, Tura S, Baccarani M. Prospective randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434-41. Crawley C, Iacobelle S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensit conditioning for myeloma: lower nonrelapse mortality but higher relapse compared with myeloablative conditioning. Blood 2007; 109: 3588-94. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, Kumar SK, Lacy MQ, Gastineau DA, Gertz MA. In vivo and in silico studies on single versus multiple transplants for multiple myeloma. Cancer Sci 2007; 98: 734-9. Einsele H, Schafer HJ, Hebart H et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411-8. Elice F, Raimondo R, Tosetto A, D’Emilio A, Di Bona E, Piccin A, Rodeghiero F. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006; 81: 426-31. Garban F, Attal M, Michallet M, Hulin C, Bourhis J, Yakoub-Agha I, Lami T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, de Prijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autpologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474-80. Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Björkstrand B et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983 –1993 and 1994 – 1998 at European Group for Blood and Marrow Transplantation Centres. Br J Haematol 2001; 113:209-16. Kröger N, Sayer HG, Schwerdtfeger R et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-24. Lahuerta JJ, Grande C, Martinez-Lopez Jet al. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de syndromes Linfoproliferativos/Trasplante Autologo de Medula Osea phase II trial. Br J Haematol 2003; 120: 296-303. Martino M, Console, G, Irrera G, Pratico G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. Am J Hematol 2006; 81: 973-8. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with haematological diseases. Blood 2003; 101: 1620-9. 103
Page 1 and 2:
Rekommandationer for knoglemarvstra
Page 3 and 4:
Vævstyper og terminologi Ved valg
Page 5 and 6:
3.valg: 9/10 allel forligelig ubesl
Page 7 and 8:
Petersdorf EW et al: Major-histocom
Page 9 and 10:
Sygdomsspecifikke overvejelser & kr
Page 11 and 12:
Non myeloablativ stamcelletransplan
Page 13 and 14:
Akutte Leukæmier ALL hos voksne AL
Page 15 and 16:
En metaanalyse af 7 studier, hvor a
Page 17 and 18:
Højrisikofaktorer • Fænotype: N
Page 19 and 20:
Kemoterapi Hoelzer, D.F (1993). The
Page 21 and 22:
unrelated transplant in first compl
Page 23 and 24:
ALL hos børn 5% blaster i knoglema
Page 25 and 26:
i det nordamerikanske register, af
Page 27 and 28:
Risikogrupper for AML i 1. CR Lavri
Page 29 and 30:
Autolog KMT Litteraturen på områd
Page 31 and 32:
Gale, R.P., Horowitz, M.M., Weiner,
Page 33 and 34:
myelogenous leukemia in first compl
Page 35 and 36:
AML hos børn
Page 37 and 38:
Eapen M, Rubinstein P, Zhang MJ, Ca
Page 39 and 40:
Point Parameter 0 0.5 1 1.5 2 Blast
Page 41 and 42:
*) Specielt i denne gruppe gælder
Page 43 and 44:
Kantarjian H, O'Brien S, Cortes J,
Page 45 and 46:
Scott BL, Sandmaier BM, Storer B, M
Page 47 and 48:
tiltagende. Patienter med RC og hø
Page 49 and 50:
Donor leukocyte infusion after hema
Page 51 and 52: � Konstitutionelle symptomer, for
Page 53 and 54: Responskriterier ved CML Responstyp
Page 55 and 56: patienter, som statistisk set vil h
Page 57 and 58: Mauro,M.J. (2006) Defining and mana
Page 59 and 60: LYMFOMER Lymfoblastært lymfom Lymf
Page 61 and 62: Der er ingen data, der indicerer at
Page 63 and 64: BURKITT'S LYMFOM Senest revideret:
Page 65 and 66: Hoelzer D, Ludwig W-D, , Thiel E et
Page 67 and 68: Der er ikke indikation for autolog
Page 69 and 70: sequential chemotherapy in poor-ris
Page 71 and 72: af immunosuppressiv beh. og DLI og
Page 73 and 74: following high-dose sequential chem
Page 75 and 76: Marginal Zone Lymfom Senest revider
Page 77 and 78: Rezvani AR, Storer B, Maris M et al
Page 79 and 80: eskriver også sammenhæng mellem i
Page 81 and 82: HCT ved refraktær sygdom (Verdonck
Page 83 and 84: transplantation for lymphoprolifera
Page 85 and 86: Perifere T-Celle Lymfomer Senest re
Page 87 and 88: Referencer: Evens AM, Gartenhaus RB
Page 89 and 90: Hodgkin Lymfom (HL) Senest revidere
Page 91 and 92: Patienter med progressiv sygdom ell
Page 93 and 94: Transplant, 12,172-183. Anderlini,P
Page 95 and 96: Allogen KMT 1. HLA-identisk søsken
Page 97 and 98: Referencer Definition Bacigalupo A,
Page 99 and 100: Paroxysmal Nocturn Haemoglobinuri,
Page 101: Autolog transplantation Myelomatose
Page 105 and 106: Myelofibrose Idiopatisk myelofibros
Page 107 and 108: Introduktion Retransplantation af b
Page 109 and 110: Den samlede konklusion kunne være,
Page 111 and 112: Thalassæmier Senest revideret nove
Page 113 and 114: thalassæmifri overlevelse på 66%
Page 115 and 116: Kronisk granulomatøs sygdom Senest
show all

12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Create successful ePaper yourself

Delete template?

Save as template?